More Cherished Moments
Innovation in healthcare is about more than just a new approach or technology. We innovate for better health of people and animals.
Search
Niha Agarwalla
My career challenge at Boehringer Ingelheim by Niha Agarwalla. Read it now!
Corporate volunteering boosts social impact - A win for all.
Boehringer Ingelheim corporate volunteers help people with disabilities. Volunteering has social impact and benefits employees, employers, and communities.
Boehringer Ingelheim attends WVPAC 2019
Boehringer Ingelheim attends and showcases its leading vaccines and services at 21st World Veterinary Poultry Association Congress
Launch of first veterinary vaccines produced in China
Swine vaccine Ingelvac PRRS MLV, produced by Boheringer Ingelheim veterinary vaccine manufacturing plant in Taizhou is now officially supplied to the China market.
ATM-Ranking-2021
Boehringer Ingelheim climbs two places. New early-stage research projects for disease areas relevant to low-to-middle income countries not reflected.
collaboration-kings-college-london
Boehringer Ingelheim and the IoPPN at King’s College London partner to progress new therapeutic concepts in major depressive disorder and schizophrenia
TwistPak Mixing platform for swine vaccines
TwistPak® allows for fresh mixing of Ingelvac CircoFLEX® and Ingelvac MycoFLEX® on farm in less than 5 seconds
Partnership to further develop pet market in China
Boehringer Ingelheim invests in partnership to further develop the pet market in China, acquires a stake in New Ruipeng Group
Closing healthcare gaps with continued vaccination campaigns
How we continue combating rabies through collaborative efforts and the use of drone delivery in rural Kenya.
Retinal Diseases
Retinal Diseases
The digital therapeutic solution halving hospitalization rates
Around 750,000 people live with chronic heart failure in Canada. The Medly program empowers patients with heart failure to manage their condition
The Goals to Improve Living with GPP
An article that describes the current goals to improve the lives of those living with generalized pustular psoriasis
Breakthrough introduction innovation pet parasiticides
In 2014, Boehringer introduced a new product, which became the first in a new class of isoxazoline products for flea and tick protection in dogs.
2024 half year results innovation progress
First half of 2024: Boehringer Ingelheim progresses pipeline at pace and reaches major milestones
Two new claims for Nexgard range in EU and Australia
Boehringer Ingelheim expands the label claims of its NexGard® brands for the treatment of two severe skin diseases in dogs in the EU and in Australia.
Our Venture Fund on the search for groundbreaking trends
The Boehringer Ingelheim Venture Fund acquires minority stakes in biotech start-ups, and even supports the majority before and during their founding.
Driving environmental solutions for people and planet
In 2022, Boehringer Ingelheim's MORE GREEN environmental sustainability initiative has reached new milestones driving our global decarbonization efforts
Approval for Aservo EquiHaler equine asthma therapy
Boehringer Ingelheim receives approval for Aservo® EquiHaler®, industry first equine asthma therapy
Covid Global Support Programm
COVID-19: Boehringer Ingelheim steps up effort with Global Support Program
What we do
Boehringer Ingelheim is a multinational corporation with divisions dedicated to Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing.
Rabies prevention local action partnering organizations
Global rabies prevention needs local action. Together with partnering organizations, we’re using pilot projects to find the right approach.
Swine
Swine
Three challenges shape future antiparasitic treatment
The three key challenges that will shape the future of antiparasitic treatment
Boehringer Ingelheim partners with PetMedix
Partnering with PetMedix on Ky9™ platform cutting edge technology as a means to bring innovative new therapies to improve health of animals